News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Pashtoon Kasi/LinkedIn
Jul 10, 2025, 20:08

Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor

Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:

“Published today JCOPO, American Society of Clinical Oncology (ASCO)

The 1st agnostic study of a PARP inhibitor:

LODESTAR: Rucaparib

Need to think about variants in Homologous Recombination Repair (HRR) Genes beyond canonical BRCA PALB2.

Novel insights. Years of effort.”

Pashtoon Kasi

Title: LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes

Authors: Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey I. Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B. Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss

Read full article.

Pashtoon Kasi

(JCOPO) Alexa B. Schrock ASCO Brennan Decker cancer Doug E. Laux E. Gabriela Chiorean Ethan S Sokol Gary K. Schwartz Geoffrey I Shapiro Hanna Tukachinsky HRR Karen McLachlan Katherine L. Nathanson Kevin K. Lin Kim A. Reiss Lara Maloney Maen Hussein Marcia Craib Nicholas J. Seewald OncoDaily Oncology Pashtoon Kasi Pashtoon Murtaza Kasi Shuoguo Wang Sriram Anbil Susan M. Domchek
Special Coverage
Voices
Aug 21, 2025, 13:39
Boston City Councilor Visited Dana-Farber to Learn About EQUAL Study
Voices
Aug 21, 2025, 13:35
David Skorton: $2 Billion Loss - NIH Funding Crisis Hits Clinical Trials
Insight
Aug 21, 2025, 13:21
Harpreet Singh: FDA’s New Draft Guidance on Radiopharmaceutical Dosing Is Here
Voices
Aug 21, 2025, 13:19
Miriam Mutebi: Why We Need to Expand Research in Palliative and Supportive Care
Insight
Aug 21, 2025, 13:16
Javier Martin-Broto: Collaborative Study Supports Mifamurtide Use in Osteosarcoma Treatment
Voices
Aug 21, 2025, 12:57
How Cancer-Induced Nerve Injury Contributes to Immunotherapy Resistance - MD Anderson Cancer Center
Voices
Aug 21, 2025, 12:34
Nirmala Bhoo Pathy: First-Ever Workshop on Patient and Financial Navigation
Immune Oncology
Aug 21, 2025, 12:34
PPP2R1A Mutations as a Biomarker in Immunotherapy: New Insights from Ovarian Clear Cell Carcinoma
Insight
Aug 21, 2025, 12:31
Alisher Kahharov: Uzbekistan's First National Breast Cancer Guideline - A Collaborative Effort with WHO and Georgian Experts
Radiotherapy
Aug 21, 2025, 12:31
New RT Paper Alert: Novel NOVEMBER Trial Puts 9-Day Breast Cancer Radiation Schedule to the Test
Opinion
Aug 21, 2025, 12:03
UICC Enhances Cancer Care with Nutrition and Psycho-Oncology Support
Voices
Aug 21, 2025, 11:40
FDA has Granted Full Market Approval for Papzimeos - NIH